Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2026)

Mirum Pharmaceuticals' Finished Goods history runs 6 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Finished Goods fell 4.39% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (down 4.39% YoY), while the FY2025 annual figure was $3.5 million, up 7.06% from the prior year.
• Finished Goods for Q1 2026 stood at $3.4 million, down from $3.5 million in the prior quarter.
• The five-year high for Finished Goods was $11.3 million in Q3 2023, with the low at $129000.0 in Q1 2023.
• The 5-year median for Finished Goods is $3.4 million (2026), against an average of $3.6 million.
• The sharpest annual moves came in 2023 and 2024: Finished Goods jumped 6200.0% in 2023, then sank 65.22% in 2024.
• Mirum Pharmaceuticals' Finished Goods stood at $214000.0 in 2022, then jumped by 4311.68% to $9.4 million in 2023, then tumbled by 65.22% to $3.3 million in 2024, then advanced by 7.06% to $3.5 million in 2025, then slipped by 2.79% to $3.4 million in 2026.
• Business Quant data shows MIRM's Finished Goods at $3.4 million in Q1 2026, $3.5 million in Q4 2025, and $2.8 million in Q3 2025.